PLXDC2

Across TCGA pan-cancer cohorts, PLXDC2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PLXDC2 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLXDC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLXDC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where PLXDC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.937	0.984	.015	13	view →
CCRCC	OS	Tertile	II,III,IV	0.892	0.568	.014	5	view →
LSCC	OS	Quartile	All	0.947	1.000	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PLXDC2–LUAD (OS)

Open the LUAD breakdown →